A24’s You Can See Everything is already shaping up to be one of the most talked-about nonfiction releases of the year. Even before its limited debut, You Can See Everything has surged to record-setting presales at Alamo Drafthouse, signaling intense audience curiosity around the Elizabeth Holmes documentary and its unusual creative pairing of Lance Oppenheim and Nathan Fielder.
The film, which centers on Holmes in the period before she reported to federal prison, has reportedly become the highest-preselling A24 title and the biggest documentary presale ever at the Sony-owned dine-in theater chain. That is a remarkable feat in a crowded theatrical market, especially as the movie currently trails only Avengers: Doomsday in Alamo’s presales rankings despite opening much sooner.
Why You Can See Everything Is Breaking Presale Records
The strong early ticket sales for You Can See Everything reflect a rare mix of cultural fascination, prestige filmmaking, and true-story intrigue. Elizabeth Holmes remains one of the most polarizing figures in modern business scandal history, and audiences continue to be drawn to fresh angles on the Theranos saga.
Several factors appear to be driving momentum:
- High-profile subject matter: Holmes and Theranos still command public attention years after the fraud case dominated headlines.
- Unconventional filmmakers: Lance Oppenheim brings documentary craft, while Nathan Fielder adds his signature deadpan unpredictability.
- Festival curiosity: The project reportedly premiered as a surprise screening at Telluride, instantly boosting prestige and word-of-mouth.
- A24 branding: The distributor has built a loyal audience for bold, conversation-starting films.
For theatergoers, You Can See Everything is not simply another documentary release. It feels like an event film in nonfiction form, which helps explain why presales are outperforming expectations.
What the Elizabeth Holmes Documentary Is About
The three-hour documentary follows Holmes during the tense period leading up to her prison sentence. Rather than retelling the Theranos rise and collapse in a conventional way, the film reportedly focuses on intimate conversations and strange, revealing interactions as Holmes and partner Billy Evans discuss the possibility of a comeback in blood testing.
That approach sets You Can See Everything apart from previous Theranos documentaries and dramatizations. Instead of revisiting the corporate downfall beat by beat, it appears to explore psychology, image, loyalty, and delusion in real time.
Nathan Fielder’s Role Adds Another Layer
Nathan Fielder’s presence is one of the project’s biggest attention magnets. Known for blending awkward humor with unsettling social observation, Fielder seems uniquely positioned to draw out contradictions in his subjects. Reports suggest his exchanges with Evans are especially revealing, giving the film a tone that may move between investigative documentary, dark comedy, and character study.
That tonal complexity is likely part of why You Can See Everything is generating such strong early buzz among critics and audiences alike.
Critical Buzz and Early Reception
Early reviews have been highly positive. The film is currently sitting at a perfect critics score on Rotten Tomatoes based on initial notices, an impressive sign for a documentary with such an unusual premise. Positive festival and industry reactions have only strengthened the sense that this is one of A24’s most distinctive releases of the year.
A recent Los Angeles screening also drew notable entertainment figures, underlining how much insider interest the project has generated. High-profile attendees and a post-screening Q&A moderated by Bill Hader helped elevate the release from documentary launch to genuine pop-culture event.
A24’s Strong Run Continues
The distributor’s recent track record has helped create trust with audiences who want original storytelling. With You Can See Everything, A24 appears to have another title that blends art-house credibility with mainstream curiosity. That combination can be especially potent in theaters, where documentaries often struggle unless they become must-see conversation pieces.
How It Compares to Other Presale Hits
Perhaps the most eye-catching detail is that You Can See Everything is currently the No. 2 presales title at Alamo Drafthouse, behind only Disney and Marvel’s Avengers: Doomsday. That comparison is striking because one is a blockbuster superhero spectacle and the other is a three-hour documentary about a disgraced startup founder.
The contrast says a lot about the current media landscape:
- Audiences are still hungry for real-life stories with larger-than-life stakes.
- Prestige documentaries can now compete with major studio releases in pre-release buzz.
- The Theranos story remains a compelling draw, particularly when framed through new access and fresh filmmaking voices.
For exhibitors, this performance may also reinforce the value of eventizing documentary cinema, especially when paired with filmmaker Q&As, special screenings, and premium theater experiences.
What This Means for the Film’s Release
With presales this strong, You Can See Everything could be poised for a breakout run beyond the usual expectations for a limited documentary opening. Strong initial demand often leads to added screenings, expanded markets, and broader media attention.
If the critical response stays strong and audience reactions match the early excitement, the film could become one of the year’s standout nonfiction theatrical releases. It may also deepen interest in documentaries that blur the line between observational filmmaking and character-driven spectacle.
Read More:
Explore More:
Final Take on You Can See Everything
At a time when theatrical audiences are selective, You Can See Everything has managed to feel urgent, strange, and culturally irresistible. Between the Elizabeth Holmes angle, Nathan Fielder’s involvement, and A24’s marketing muscle, the documentary has all the ingredients of a breakout specialty hit.
If the presales are any indication, You Can See Everything will be much more than a niche documentary release. It is arriving as a major conversation starter—and possibly one of the most unusual box office stories of the season.
